

Roberto Crocchiolo

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1664104/roberto-crocchiolo-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65
papers

2,157
citations

24
h-index

45
g-index

68
ext. papers

2,526
ext. citations

4.3
avg, IF

3.97
L-index

#	Paper	IF	Citations
65	Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. <i>Lancet Oncology, The</i> , 2009 , 10, 489-500	21.7	400
64	Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). <i>Lancet Infectious Diseases, The</i> , 2019 , 19, e260-e272	25.5	137
63	Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 724-9	4.7	120
62	Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. <i>Blood</i> , 2009 , 114, 1437-44	2.2	115
61	Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. <i>Blood</i> , 2008 , 112, 3488-99	2.2	104
60	Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. <i>Blood</i> , 2015 , 125, 2855-64	2.2	100
59	Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 118-24	4.7	74
58	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. <i>Clinical Infectious Diseases</i> , 2017 , 65, 1884-1896	11.6	63
57	Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options. <i>Hematological Oncology</i> , 2009 , 27, 61-70	1.3	61
56	Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial. <i>British Journal of Haematology</i> , 2010 , 150, 226-9	4.5	58
55	Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas. <i>Ophthalmology</i> , 2011 , 118, 24-8	7.3	57
54	Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases. <i>Cancer</i> , 2013 , 119, 986-92	6.4	51
53	Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma?. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5134-6; author reply 5136-7	2.2	48
52	CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 382-6	4.7	47
51	Guidelines from the 2017 European Conference on Infections in Leukaemia for management of HHV-6 infection in patients with hematologic malignancies and after hematopoietic stem cell transplantation. <i>Haematologica</i> , 2019 , 104, 2155-2163	6.6	44
50	Reconstitution of natural killer cells in HLA-matched HSCT after reduced-intensity conditioning: impact on clinical outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 429-39	4.7	41
49	High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. <i>Leukemia and Lymphoma</i> , 2008 , 49, 2042-7	1.9	41

48	Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 370-4	4.7	37
47	Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma. <i>Experimental Hematology</i> , 2012 , 40, 521-7	3.1	33
46	Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1228-34	1.9	31
45	Unpredictability of intravenous busulfan pharmacokinetics in children undergoing hematopoietic stem cell transplantation for advanced beta thalassemia: limited toxicity with a dose-adjustment policy. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 622-8	4.7	31
44	Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation. <i>Cancer</i> , 2010 , 116, 5001-11	6.4	30
43	Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies. <i>Cancer</i> , 2015 , 121, 1809-16	6.4	28
42	Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2008 , 49, 727-33	1.9	25
41	Significantly higher frequencies of alloreactive CD4+ T cells responding to nonpermissive than to permissive HLA-DPB1 T-cell epitope disparities. <i>Blood</i> , 2010 , 116, 1991-2	2.2	23
40	24-Hydroxycholesterol participates in pancreatic neuroendocrine tumor development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E6219-E6227	11.5	22
39	Impact of reduced-intensity conditioning allogeneic stem cell transplantation on women's fertility. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 704-10	2	21
38	National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1106-12	1.9	21
37	A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. <i>American Journal of Hematology</i> , 2014 , 89, 83-7	7.1	20
36	Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2012 , 87, 1074-8	7.1	20
35	Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen: Outcomes of patients admitted to intensive care unit. <i>Journal of Critical Care</i> , 2015 , 30, 1107-13	4	19
34	Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes. <i>International Journal of Cancer</i> , 2013 , 132, 2557-66	7.5	19
33	In vivo and in vitro effects of different anaesthetics on platelet function. <i>British Journal of Haematology</i> , 2004 , 125, 79-82	4.5	19
32	Bendamustine combined with donor lymphocytes infusion in Hodgkin's lymphoma relapsing after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1444-7	4.7	18
31	Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma. <i>American Journal of Hematology</i> , 2013 , 88, 370-4	7.1	18

30	Platelet transfusion refractoriness in highly immunized beta thalassemia children undergoing stem cell transplantation. <i>Pediatric Transplantation</i> , 2010 , 14, 393-401	1.8	17
29	Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. <i>Bone Marrow Transplantation</i> , 2018 , 53, 422-430	4.4	15
28	Human Herpesvirus 6 replication predicts Cytomegalovirus reactivation after allogeneic stem cell transplantation from haploidentical donor. <i>Journal of Clinical Virology</i> , 2016 , 84, 24-26	14.5	15
27	Effect of fibrinogen concentration and platelet count on the inhibitory effect of abciximab and tirofiban. <i>Thrombosis and Haemostasis</i> , 2003 , 89, 348-354	7	14
26	Comparable outcomes between unrelated and related donors after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with high-risk multiple myeloma. <i>European Journal of Haematology</i> , 2012 , 88, 497-503	3.8	11
25	Impact of pretransplant donor and recipient cytomegalovirus serostatus on outcome for multiple myeloma patients undergoing reduced intensity conditioning allogeneic stem cell transplantation. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013 , 5, e2013026	3.2	11
24	Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1560-5	4.7	10
23	Desensitization with plasma exchange in a patient with human leukocyte antigen donor-specific antibodies before T-cell-replete haploidentical transplantation. <i>Transfusion</i> , 2016 , 56, 1096-1100	2.9	7
22	Nuclear receptor ligands induce TREM-1 expression on dendritic cells: analysis of their role in tumors. <i>Oncolimmunology</i> , 2019 , 8, 1554967	7.2	7
21	Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2015 , 7, e2015048	3.2	6
20	Therapeutic management of ocular adnexal MALT lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 1073-83	4	6
19	Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experience. <i>Experimental Hematology</i> , 2013 , 41, 17-27	3.1	5
18	Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients. <i>Haematologica</i> , 2015 , 100, e423-7	6.6	5
17	JC Virus Leuko-Encephalopathy in Reduced Intensity Conditioning Cord Blood Transplant Recipient with a Review of the Literature. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012 , 4, e2012043	3.2	5
16	Allogeneic transplant for myeloma in the era of new drugs: have the outcomes improved?. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1630-2	1.9	5
15	The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m ² intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2315-20	1.9	4
14	Successful treatment of post-transplant Epstein-Barr virus-related meningoencephalitis by intravenous rituximab monotherapy. <i>Leukemia and Lymphoma</i> , 2012 , 53, 2063-5	1.9	4
13	Similar favorable outcome of pegfilgrastim overdose in patients with different age and underlying disease. <i>Haematologica</i> , 2010 , 95, 684-5	6.6	3

12	A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling. <i>Transplant Infectious Disease</i> , 2018 , 20, e12906	2.7	2
11	Impact of antithymocyte globulin on the need for platelet transfusions during reduced-intensity conditioning administration before allogeneic stem cell transplantation. <i>Experimental Hematology</i> , 2013 , 41, 503-5	3.1	2
10	Feasibility and Efficacy of CD45RA+ Depleted Donor Lymphocytes Infusion After Haploidentical Transplantation With Post-Transplantation Cyclophosphamide in Patients With Hematological Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 478.e1-478.e5		2
9	Preliminary Results of a Combined Score Based on sIL2-RII and TIM-3 Levels Assayed Early After Hematopoietic Transplantation. <i>Frontiers in Immunology</i> , 2019 , 10, 3158	8.4	1
8	Response to immunosuppressive treatment predicts outcome in patients with chronic graft-versus-host disease: a single-center analysis of longitudinal data. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 576-83	4.7	1
7	Poor autologous mobilization status does not impact on hematological recovery but affects outcome after allogeneic stem cell transplant for lymphoma and myeloma. <i>Leukemia and Lymphoma</i> , 2013 , 54, 417-20	1.9	1
6	Clofarabine and Treosulfan as Conditioning for Matched Related and Unrelated Hematopoietic Stem Cell Transplantation: Results from the Clo3o Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 316-322	4.7	1
5	SARS-COV-2 SCREENING IN ALLOGENEIC HEMATOPOIETIC STEM CELL DONORS: IMPLICATIONS FOR THE EVALUATION PROCESS AND ELIGIBILITY.. <i>Hematology, Transfusion and Cell Therapy</i> , 2021 ,	1.6	1
4	Use of DPB1 T-cell epitope algorithm among italian transplant centers: A survey on behalf of Associazione Italiana di Immunogenetica e Biologia dei Trapianti. <i>Hla</i> , 2021 , 98, 114-121	1.9	0
3	Current IST-free/relapse-free survival as a new endpoint after allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2020 , 99, 1149-1150	3	
2	The number of HLA confirmatory tests during unrelated donor search as a driver for the evaluation of back-up haploidentical donor(s). <i>Transfusion and Apheresis Science</i> , 2020 , 59, 102766	2.4	
1	Is SARS-CoV-2 screening still necessary before hematopoietic stem cell donation? Observations from a single center and review of the literature.. <i>Transfusion and Apheresis Science</i> , 2022 , 103448	2.4	